The IPRO-led Atlantic Quality Innovation Network (AQIN) Drug Safety Team will implement standardized pharmacist-patient counseling and direct patient- and prescriber-level interventions to decrease the risk of opioid-related adverse events across New York, the District of Columbia and South Carolina. The two-year project will provide pharmacist counseling to patients using a standardized counseling checklist and address misuse and overdose potential. Desired outcomes include an increase in the number of naloxone prescriptions dispensed by participating pharmacies and a decrease in the incidence of opioid-related emergency department visits for Medicare beneficiaries. Chronic Kidney Disease (CKD) is an under-diagnosed, insidious disease with dramatic long-term public health costs and consequences. Since CKD is asymptomatic until its later stages, it is rarely recognized by primary care clinicians until it progresses and becomes a chronic condition. The two-year IPRO project will engage clinicians, the community, patients, caregivers, and grassroots stakeholders in the goals of increasing CKD screenings, delaying disease progression, and improving patient outcomes. IPRO’s multi-faceted approach aims to elevate CKD diagnosis and management to the front lines of preventative health for New Yorkers. AQIN-NY will work with providers and community-based organizations to achieve two bold aims within the two-year period: (1) 10% reduction in the rate of patients that progress from CKD Stage 3 to Stage 4 and (2) increase CKD screenings for at least 40% of project participants.